Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kunihiro Yamaoka

Showing results (1-10 of 157) with videos related to

Pageof 16
Sort By:
Nihon Rinsho Men'Eki Gakkai Kaishi = Japanese Journal of Clinical Immunology|June 21, 2016
Relation between disease modifying anti-rheumatic drugs and herpes zoster in rheumatoid arthritisKunihiro Yamaoka
Clinical Calcium|April 28, 2016
[Potential of bone regenerative therapy with mesenchymal stem cells in rheumatoid arthritis]Kunihiro Yamaoka
Drug Safety|May 20, 2016
Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes ZosterKunihiro Yamaoka
Expert Review of Clinical Immunology|April 19, 2019
Tofacitinib for the treatment of rheumatoid arthritis: an updateKunihiro Yamaoka
Current Opinion in Chemical Biology|March 20, 2016
Janus kinase inhibitors for rheumatoid arthritisKunihiro Yamaoka
Clinical Calcium|May 8, 2018
[Diagnosis and treatment of rheumatoid arthritis:toward the best practice. Best practice with JAK inhibitors.]Kunihiro Yamaoka
Nihon Rinsho Men'Eki Gakkai Kaishi = Japanese Journal of Clinical Immunology|May 1, 2009
Jak inhibitor ; possibility and mechanism as a new disease modifying anti-rheumatic drugKunihiro Yamaoka, Yoshiya Tanaka
Immunological Medicine|July 11, 2020
Developmental process in diffuse psychological/neuropsychiatric manifestations of neuropsychiatric systemic lupus erythematosusYoshiyuki Arinuma, Kunihiro Yamaoka
Nihon Rinsho. Japanese Journal of Clinical Medicine|August 22, 2013
[JAK inhibitor]Kunihiro Yamaoka, Yoshiya Tanaka
Expert Opinion on Pharmacotherapy|November 6, 2013
Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinibKunihiro Yamaoka, Yoshiya Tanaka
Pageof 16

Showing results (1-10 of 157) with videos related to

Sort By:
Pageof 16
Nihon Rinsho Men'Eki Gakkai Kaishi = Japanese Journal of Clinical Immunology|June 21, 2016
Relation between disease modifying anti-rheumatic drugs and herpes zoster in rheumatoid arthritisKunihiro Yamaoka
Clinical Calcium|April 28, 2016
[Potential of bone regenerative therapy with mesenchymal stem cells in rheumatoid arthritis]Kunihiro Yamaoka
Drug Safety|May 20, 2016
Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes ZosterKunihiro Yamaoka
Expert Review of Clinical Immunology|April 19, 2019
Tofacitinib for the treatment of rheumatoid arthritis: an updateKunihiro Yamaoka
Current Opinion in Chemical Biology|March 20, 2016
Janus kinase inhibitors for rheumatoid arthritisKunihiro Yamaoka
Clinical Calcium|May 8, 2018
[Diagnosis and treatment of rheumatoid arthritis:toward the best practice. Best practice with JAK inhibitors.]Kunihiro Yamaoka
Nihon Rinsho Men'Eki Gakkai Kaishi = Japanese Journal of Clinical Immunology|May 1, 2009
Jak inhibitor ; possibility and mechanism as a new disease modifying anti-rheumatic drugKunihiro Yamaoka, Yoshiya Tanaka
Immunological Medicine|July 11, 2020
Developmental process in diffuse psychological/neuropsychiatric manifestations of neuropsychiatric systemic lupus erythematosusYoshiyuki Arinuma, Kunihiro Yamaoka
Nihon Rinsho. Japanese Journal of Clinical Medicine|August 22, 2013
[JAK inhibitor]Kunihiro Yamaoka, Yoshiya Tanaka
Expert Opinion on Pharmacotherapy|November 6, 2013
Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinibKunihiro Yamaoka, Yoshiya Tanaka
Pageof 16